Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research
Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors
Stay informed and receive company updates straight to your inbox.